scispace - formally typeset
Search or ask a question

Showing papers by "Huib N. Caron published in 2014"


Journal ArticleDOI
TL;DR: Investigating the growth characteristics and confirmed tumour-forming potential of eight newly-derived neuroblastoma TICs cultured under serum-free conditions establish that they are relevant and useful Neuroblastoma tumour models.

53 citations


Journal ArticleDOI
TL;DR: The aim was to investigate the current screening strategy and the prevalence of endocrine disorders in survivors of a childhood brain tumor outside of the hypothalamic‐pituitary region, within the first 5 years after diagnosis.
Abstract: Introduction Childhood brain tumor survivors (CBTS) are at increased risk to develop endocrine disorders. Alerted by two cases who experienced delay in diagnosis of endocrine deficiencies within the first 5 years after brain tumor diagnosis, our aim was to investigate the current screening strategy and the prevalence of endocrine disorders in survivors of a childhood brain tumor outside of the hypothalamic-pituitary region, within the first 5 years after diagnosis. Procedures Firstly, we performed a retrospective study of 47 CBTS treated in our center, diagnosed between 2008 and 2012. Secondly, the literature was reviewed for the prevalence of endocrine disorders in CBTS within the first 5 years after diagnosis. Results Of 47 CBTS eligible for evaluation, in 34% no endocrine parameters had been documented at all during follow up. In the other 66%, endocrine parameters had been inconsistently checked, with different parameters at different time intervals. In 19% of patients an endocrine disorder was found. At literature review 22 studies were identified. The most common reported endocrine disorder within the first 5 years after diagnosis was growth hormone deficiency (13–100%), followed by primary gonadal dysfunction (0–91%) central hypothyroidism (0–67%) and primary/subclinical hypothyroidism (range 0–64%). Conclusion Endocrine disorders are frequently seen within the first 5 years after diagnosis of a childhood brain tumor outside of the hypothalamic-pituitary region. Inconsistent endocrine follow up leads to unnecessary delay in diagnosis and treatment. Endocrine care for this specific population should be improved and standardized. Therefore, high-quality studies and evidence based guidelines are warranted. Pediatr Blood Cancer 2014;61:2285–2289. © 2014 Wiley Periodicals, Inc.

19 citations


Journal ArticleDOI
06 Dec 2014-Blood
TL;DR: The data suggest that BCP-ALL patients with RAS-activating mutations may benefit from treatment with Trametinib/Sorafenib and strongly argue to implement these inhibitors in combination with prednisolone.

3 citations